Radiofluorinated pyrimidine-2,4,6-triones as molecular probes for noninvasive MMP-targeted imaging.
Breyholz HJ, Wagner S, Faust A, Riemann B, Höltke C, Hermann S, Schober O, Schäfers M, Kopka K
Research article (journal)Abstract
Matrix metalloproteinases (MMPs) are zinc- and calcium-dependent endopeptidases. Representing a subfamily of the metzincin superfamily, MMPs are involved in the proteolytic degradation of components of the extracellular matrix. Unregulated MMP expression, MMP dysregulation and locally increased MMP activity are common features of various diseases, such as cancer, atherosclerosis, stroke, arthritis, and others. Therefore, activated MMPs are suitable biological targets for the specific visualization of such pathologies, in particular by using radiolabeled MMP inhibitors (MMPIs). The aim of this work was to develop a radiofluorinated molecular probe for noninvasive in vivo imaging for the detection of up-regulated levels of activated MMPs in the living organism. Fluorinated MMPIs (26, 31 and 38) based on the pyrimidine-2,4,6-trione lead structure RO 28-2653 (1) were synthesized, and their MMP inhibition potency was evaluated in vitro. The radiosynthesis and the in vivo biodistribution of the first (18)F-labeled prototype, MMP-targeted tracer [(18)F]26, suitable for molecular imaging by means of positron emission tomography (PET) were realized.
Details about the publication
Authors from the University of Münster
| Breyholz, Hans-Jörg | Clinic for Nuclear Medicine |
| Hermann, Sven | Clinic for Nuclear Medicine |
| Höltke, Carsten | Clinic of Radiology |
| Kopka, Klaus | Clinic for Nuclear Medicine |
| Schäfers, Michael | Clinic for Nuclear Medicine European Institute of Molecular Imaging (EIMI) |
| Schober, Otmar | Clinic for Nuclear Medicine |
| Wagner, Stefan | Clinic for Nuclear Medicine |
| Wiethoff genannt Riemann, Burkhard | Clinic for Nuclear Medicine |